Last updated 12 days ago
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
7140 patients around the world
Available in Argentina, Mexico, Brazil
Eli Lilly and Company
108Research sites
7140Patients around the world
This study is for people with
Cardiovascular disease
Renal disease
Chronic kidney disease
Requirements for the patient
From 50 Years
All Gender
Medical requirements
- Have established ASCVD and/or CKD.
- Have type 1 diabetes.Have had a major heart condition within 60 days prior to screening.Have New York Heart Association Functional Classification Class IV heart failure.
Sites
Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Médica - Rosario, Santa Fe
Recruiting
Organización Médica de Investigación (OMI)
Recruiting
STAT Research - CABA
Recruiting
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
Recruiting
Centro Médico Viamonte SRL - CABA, Buenos Aires
Recruiting
Centro Médico Maffei - CABA, Buenos Aires
Recruiting
Instituto de Investigaciones Clínicas Córdoba
Recruiting
Instituto Médico Damic S.R.L.
Recruiting
Sociedad de Beneficencia Hospital Italiano - Córdoba
Recruiting
CEDIMBA - DIM Clínica Privada - Buenos Aires
Recruiting
StudyATTAIN-Outcomes
SponsorEli Lilly and Company
Study typeInterventional
Conditions
Cardiovascular diseaseChronic kidney disease
Requirements
From 50 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07241390
